Department of Molecular Neurobiology
Prof Lucas has over 20 years of experience working in the field of Huntington’s disease. He has established his own research group at the CBMSO, based around the study of the molecular basis of Huntington’s disease and other neurological diseases. He has public as well as private funding, with projects from the National Science Department, CIBERNED and the BBVA Foundation. He has contributed to almost 50 publications in the last 5 years including Nature Medicine, EMBO Journal, Cell and PNAS among other high impact publications. Prof Lucas has previous industry experience (Oryzon) testing a specific inhibitor of LSD1 to check its impact on Huntington’s disease phenotype in mouse models (R6/1). Prof Lucas’s present team comprises 2 postdoctoral researcher, 3 PhD students and 2 research assistants. He has supervised 6 PhD students and 6 postdoctoral researchers.
He will be responsible for the study of the role of P2X7R in Huntington’s disease and the effect of P2X7R antagonism or genetic manipulation in Huntington’s disease mouse models. He will further be responsible for establishing blood purines and P2X7R down-stream inflammation markers as early diagnostics for Huntington’s disease in patients.
The Centre for Biomedical Research in Neurodegenerative Diseases (CIBERNED) emerged in 2006 as heir to the Centre for Research in Neurological Diseases (CIEN). It was the first Network Centre in Spain and, currently, the CIBERNED-CIEN Foundation partnership is the only research centre in Spain (and one of the few in the world) integrated into the international network of Centres of Excellence in Neurodegeneration (CoEN), an initiative arising from the European Union Joint Programme for Research in Neurodegenerative Diseases (JPND). This joint program constitutes an innovative collaborative research initiative created to address the growing challenges posed by this group of diseases. Its goal is to boost the impact of research by aligning existing national research programs and identifying the common objectives whose scope would benefit through joint action.
CIBERNED was born with the idea of creating a Centre for Translational Research, with a multidisciplinary and multi-institutional philosophy in which basic, clinical and population studies are integrated in order to develop a single joint research program, focusing on certain diseases of great importance for the National Health System that either for its prevalence or because of its social impact, are considered strategic. CIBERNED currently consists of 58 research groups supported by different universities, hospitals and the Research Council (CSIC), each led by a principal investigator. CIBERNED is a network research centre, composed of research groups belonging to different Administrations and affiliated Institutions: researchers physically work in the parent institutions they belong to while simultaneously and actively participating in CIBERNED’s own cooperative research agenda.